OneMedNet Reports Strong Momentum and Industry Excitement at RSNA

MINNEAPOLIS, Dec. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), the leading curator and provider of one of the world's largest regulatory-grade, AI-ready Real-World Data (RWD) network, today announced significant engagement and growing commercial traction following a productive four days at the Radiological Society of North America (RSNA) Annual Meeting. Throughout the event, it was clear that hospitals, imaging centers, and life sciences innovators are eager to join the OneMedNet Network and utilize its updated iRWD platform, powered by Palantir Foundry.

RSNA 2025 provided clear market validation for OneMedNet across provider and life sciences ecosystems, affirming the Company's strategy amid increasing demand for high-quality, regulatory-grade RWD.

Healthcare providers expressed strong interest in partnering with OneMedNet to derive value from their clinical data assets while supporting diverse patient representation in research, Real-World Evidence (RWE) programs, and observational studies. Attendees highlighted OneMedNet's efficient, straightforward deployment model—a key advantage—along with opportunities for revenue streams through compliant data sharing.

“OneMedNet has consistently demonstrated an exceptional ability to rapidly source the clinical data we require and curate it with precision to our exact specifications. Their speed, data quality, and commitment to regulatory-grade standards are unmatched. This level of execution enables our teams to accelerate evidence generation and focus on delivering meaningful innovation. It’s why we continue to return to OneMedNet for our Real-World Data needs—they are a trusted strategic partner in our mission to advance impactful healthcare solutions.” says Shahzad Rauf, Chief Strategy Officer, Xylexa

Life sciences companies and AI developers demonstrated keen interest in the next-generation iRWD platform, supported by Palantir Foundry. Key features noted included its ability to provide large-scale, high-fidelity multimodal datasets with speed, comprehensive longitudinal coverage, and strong clinical accuracy. The platform's AI-enabled cohort discovery capabilities – reducing feasibility assessments from weeks to minutes– were identified as a valuable differentiator for research, post-market surveillance, and market access efforts.